Procedure guideline for prostate-specific membran antigen targeting positron emission tomography (PSMA-PET) in prostate cancer

被引：0
作者：
Robin, P. [1 ,2 ,5 ]
Bailly, C. [3 ]
Palard-Novello, X. [4 ]
机构：
[1] CHU Brest, Serv Med Nucl, 2,Ave Foch, F-29269 Brest, France
[2] Univ Brest, UMR 1304, Inserm, CHU Brest, Brest, France
[3] CHU Nantes, Serv Med Nucl, Nantes, France
[4] Univ Rennes, CLCC Eugene Marquis, Inserm, LTSI UMR 1099, Rennes, France
[5] Univ Brest, CHRU Brest, Serv Med Nucl, Inserm,UMR 1304,GETBO,Ctr Hosp & Univ Brest, 2, Ave Foch, F-29609 Brest, France
来源：
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2023年 / 47卷 / 05期
关键词：
Positron Emission Tomography; Prostate specific membran antigen receptor; Gallium-68; Fluor-18; RADIATION-DOSIMETRY; BIODISTRIBUTION; DIAGNOSIS; INHIBITOR;
D O I：
10.1016/j.mednuc.2023.07.004
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
Prostate-specific membrane antigen targeting positron emission tomography (PSMA-PET) is nowadays widely used for the management of patients with prostate cancer during natural history of the disease. Several radiopharmaceuticals labeled with Gallium-68 and Fluor-18 are now available in France, some of which have obtained marketing authorization in various indications. Patient preparation and image acquisition protocols differ from one radiopharmaceutical to another. The objective of this article is to provide practical guidelines regarding PET-PSMA protocols, for radiopharmaceuticals labeled with Gallium 68 or Fluor-18, to facilitate implementation in clinical routine in nuclear medicine departments in France.
引用
收藏
页码：266 / 269
页数：4
相关论文
共 14 条
[1]   PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].
Afshar-Oromieh, A. ;
Malcher, A. ;
Eder, M. ;
Eisenhut, M. ;
Linhart, H. G. ;
Hadaschik, B. A. ;
Holland-Letz, T. ;
Giesel, F. L. ;
Kratochwil, C. ;
Haufe, S. ;
Haberkorn, U. ;
Zechmann, C. M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495
[2]   The Clinical Impact of Additional Late PET/CT Imaging with 68Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer [J].
Afshar-Oromieh, Ali ;
Sattler, Lars Peter ;
Mier, Walter ;
Hadaschik, Boris A. ;
Debus, Juergen ;
Holland-Letz, Tim ;
Kopka, Klaus ;
Haberkorn, Uwe .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (05) :750-755
[3]   The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J].
Afshar-Oromieh, Ali ;
Hetzheim, Henrik ;
Kratochwil, Clemens ;
Benesova, Martina ;
Eder, Matthias ;
Neels, Oliver C. ;
Eisenhut, Michael ;
Kuebler, Wolfgang ;
Holland-Letz, Tim ;
Giesel, Frederik L. ;
Mier, Walter ;
Kopka, Klaus ;
Haberkorn, Uwe .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1697-1705
[4]   Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer [J].
Benesova, Martina ;
Schaefer, Martin ;
Bauder-Wuest, Ulrike ;
Afshar-Oromieh, Ali ;
Kratochwil, Clemens ;
Mier, Walter ;
Haberkorn, Uwe ;
Kopka, Klaus ;
Eder, Matthias .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :914-920
[5]   68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging [J].
Eder, Matthias ;
Schaefer, Martin ;
Bauder-Wuest, Ulrike ;
Hull, William-Edmund ;
Waengler, Carmen ;
Mier, Walter ;
Haberkorn, Uwe ;
Eisenhut, Michael .
BIOCONJUGATE CHEMISTRY, 2012, 23 (04) :688-697
[6]   PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 [J].
Fendler, Wolfgang P. ;
Eiber, Matthias ;
Beheshti, Mohsen ;
Bomanji, Jamshed ;
Calais, Jeremie ;
Ceci, Francesco ;
Cho, Steve Y. ;
Fanti, Stefano ;
Giesel, Frederik L. ;
Goffin, Karolien ;
Haberkorn, Uwe ;
Jacene, Heather ;
Koo, Phillip J. ;
Kopka, Klaus ;
Krause, Bernd J. ;
Lindenberg, Liza ;
Marcus, Charles ;
Mottaghy, Felix M. ;
Oprea-Lager, Daniela E. ;
Osborne, Joseph R. ;
Piert, Morand ;
Rowe, Steven P. ;
Schoeder, Heiko ;
Wan, Simon ;
Wester, Hans-Jurgen ;
Hope, Thomas A. ;
Herrmann, Ken .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (05) :1466-1486
[7]   68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 [J].
Fendler, Wolfgang P. ;
Eiber, Matthias ;
Beheshti, Mohsen ;
Bomanji, Jamshed ;
Ceci, Francesco ;
Cho, Steven ;
Giesel, Frederik ;
Haberkorn, Uwe ;
Hope, Thomas A. ;
Kopka, Klaus ;
Krause, Bernd J. ;
Mottaghy, Felix M. ;
Schoder, Heiko ;
Sunderland, John ;
Wan, Simon ;
Wester, Hans-Juergen ;
Fanti, Stefano ;
Herrmann, Ken .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (06) :1014-1024
[8]   F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients [J].
Giesel, Frederik L. ;
Hadaschik, B. ;
Cardinale, J. ;
Radtke, J. ;
Vinsensia, M. ;
Lehnert, W. ;
Kesch, C. ;
Tolstov, Y. ;
Singer, S. ;
Grabe, N. ;
Duensing, S. ;
Schaefer, M. ;
Neels, O. C. ;
Mier, W. ;
Haberkorn, U. ;
Kopka, K. ;
Kratochwil, C. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (04) :678-688
[9]   Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy [J].
Herrmann, Ken ;
Bluemel, Christina ;
Weineisen, Martina ;
Schottelius, Margret ;
Wester, Hans-Juergen ;
Czernin, Johannes ;
Eberlein, Uta ;
Beykan, Seval ;
Lapa, Constantin ;
Riedmiller, Hubertus ;
Krebs, Markus ;
Kropf, Saskia ;
Schirbel, Andreas ;
Buck, Andreas K. ;
Lassmann, Michael .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :855-861
[10]   French AFU Cancer Committee Guidelines- Update 2022-2024: prostate cancer- Diagnosis and management of localised disease [J].
Ploussard, G. ;
Fiard, G. ;
Barret, E. ;
Brureau, L. ;
Crehange, G. ;
Dariane, C. ;
Fromont, G. ;
Gauthe, M. ;
Mathieu, R. ;
Renard-Penna, R. ;
Roubaud, G. ;
Rozet, F. ;
Ruffion, A. ;
Sargos, P. ;
Beauval, J-B ;
Roupret, M. .
PROGRES EN UROLOGIE, 2022, 32 (15) :1275-1372
12